New Immunotherapy Shows Promise for Aggressive Blood Cancer
New immunotherapy Drug Shows Promise for Aggressive Blood Cancer
AZD0486 Offers Hope for Patients with Relapsed diffuse Large B-Cell Lymphoma
A groundbreaking immunotherapy drug is offering new hope for patients battling a notably aggressive form of blood cancer. AZD0486,a bispecific antibody,has shown promising results in treating diffuse large B-cell lymphoma (DLBCL),even in patients who have not responded to previous therapies,including CAR-T cell treatment.
These findings, presented at the American Society of Hematology annual meeting, mark a notable advancement in the fight against this challenging disease.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, accounting for roughly 30% of all cases. While many patients initially respond well to treatment, those who relapse or develop resistance to standard therapies face limited options. AZD0486 may provide a much-needed lifeline for these individuals.
Sameh Gaballa, MD
AZD0486 works by targeting specific proteins on both lymphoma cells and T cells, effectively bringing the body’s own immune system into direct contact with the cancer. This targeted approach allows for a powerful attack on the tumor.
In an ongoing phase 1 clinical trial, AZD0486 demonstrated an extraordinary overall response rate of 47%, with a complete response rate of 42% in patients.
“We’re witnessing durable responses in patients who have tired all other treatment options,” said Sameh Gaballa,MD,a medical oncologist at Moffitt Cancer Center who presented the trial data. “As an off-the-shelf drug, it has the potential to reach more patients in need of new treatment options, without the delays frequently enough associated with CAR T-cell manufacturing.”
Importantly, AZD0486 has been generally well-tolerated by patients. Researchers have implemented a novel dosing strategy to minimize the risk of severe side effects commonly seen with similar therapies.
While these early results are encouraging, Dr. Gaballa emphasizes the need for larger studies to confirm the drug’s long-term effectiveness and safety. The clinical trial is ongoing, with researchers currently evaluating higher doses of AZD0486 in this patient population.
New Hope for Relapsed Lymphoma Patients: Immunotherapy Shows Promise in Early Trial
NewsDirectory3.com – A new immunotherapy drug, AZD0486, is offering renewed hope for patients battling relapsed diffuse large B-cell lymphoma (DLBCL), a particularly aggressive blood cancer.
Early results from a phase 1 clinical trial presented at the American Society of Hematology annual meeting revealed remarkable efficacy, especially in patients who had not responded to prior therapies, including CAR-T cell treatment.
AZD0486, a bispecific antibody, functions by targeting specific proteins on both lymphoma cells and T cells, effectively enlisting the body’s own immune system to attack the cancer.
“We’re witnessing durable responses in patients who have tired all othre treatment options,” said dr. Sameh Gaballa, a medical oncologist at Moffitt Cancer Center who presented the trial data. “As an off-the-shelf drug, it has the potential to reach more patients in need of new treatment options, without the delays frequently associated wiht CAR T-cell manufacturing.”
The trial demonstrated an remarkable overall response rate of 47%, with a complete response rate of 42% in patients. Importantly, the drug has been well-tolerated, thanks to a novel dosing strategy designed to minimize side effects.
While these results are promising, Dr. Gaballa stresses the need for larger studies to confirm the long-term efficacy and safety of AZD0486.The ongoing trial is currently evaluating higher doses of the drug in this patient population.